Inhibition of experimental corneal neovascularization by using subconjunctival injection of bevacizumab (Avastin).
about
Secreted frizzled-related protein 4: an angiogenesis inhibitor.Effects of topical and subconjunctival bevacizumab in high-risk corneal transplant survivalEffects of rat anti-VEGF antibody in a rat model of corneal graft rejection by topical and subconjunctival routes.Intrastromal delivery of bevacizumab using microneedles to treat corneal neovascularization.Corneal neovascularization: an anti-VEGF therapy review.Cytotoxic properties of sunitinib and sorafenib on human corneal epithelial cells.Mechanisms controlling the effects of bevacizumab (avastin) on the inhibition of early but not late formed corneal neovascularization.Ocular distribution, spectrum of activity, and in vivo viral neutralization of a fully humanized anti-herpes simplex virus IgG Fab fragment following topical applicationInhibition of corneal neovascularization with the combination of bevacizumab and plasmid pigment epithelium-derived factor-synthetic amphiphile INTeraction-18 (p-PEDF-SAINT-18) vector in a rat corneal experimental angiogenesis model.Topical bevacizumab in the treatment of corneal neovascularization: results of a prospective, open-label, noncomparative study.Topically administered bevacizumab had longer standing anti-angiogenic effect than subconjunctivally injected bevacizumab in rat corneal neovacularization.Corneal neovascularization during experimental fungal keratitis.Effect of subconjuctival and intraocular bevacizumab injection on angiogenic gene expression levels in a mouse model of corneal neovascularization.Comparison of different doses of subconjunctival sunitinib with bevacizumab in the treatment of corneal neovascularization in experimental rats.Corneal penetration of topical and subconjunctival bevacizumab.Effect of subconjunctival and intraocular bevacizumab injections on corneal neovascularization in a mouse model.Prevention of corneal neovascularization: comparison of different doses of subconjunctival bevacizumab with its topical form in experimental rats.The effect of different doses of subconjunctival bevacizumab injection on corneal neovascularization.Topical dihydroartemisinin inhibits suture-induced neovascularization in rat corneas through ERK1/2 and p38 pathways.Evaluating the safety of intracameral bevacizumab application using oxidative stress and apoptotic parameters in corneal tissue.Efficacy of topical bevacizumab in high-risk corneal transplant survival.Subconjunctival gene delivery of the transcription factor GA-binding protein delays corneal neovascularization in a mouse model.The Boston Ocular Surface Prosthesis as a novel drug delivery system for bevacizumab.Topical Timolol Inhibits Corneal Neovascularization in Rabbits.Anti-VEGF therapy (bevacizumab) for sulfur mustard-induced corneal neovascularization associated with delayed limbal stem cell deficiency in rabbits.
P2860
Q33703825-979CAFA8-4021-407C-B6B0-83F815C499ADQ33845555-0A5CF804-F179-4D6C-94DB-8653572EA057Q34493789-71BBC85B-42F6-44D7-91B7-78EFC2D43945Q34511156-273D54B3-1A5A-43E2-9E8F-05DD297F9CDAQ34641522-08C41097-7363-4641-A658-F2231CFC0938Q35001062-95EB31FD-D8E8-4247-A182-CFF24B8D28A6Q35143121-1F0ECC93-D5CF-48BD-823C-EC812EEC357DQ35806468-67125AC6-0678-48C1-A5EA-62E11C20ECA7Q36820584-EF549279-3974-4E10-9DCB-C8AD96185F65Q37244781-966C6F4B-0298-4805-B4F9-5396DE96247CQ37256827-F5C97190-E7DC-4F54-8EC5-430469312892Q37373833-850508B0-AE44-4CED-BE75-1EBC379E1998Q37425259-6E760A26-10C0-45D9-9C96-F1E0841781A8Q37721914-21F35ED9-8602-49E6-9497-C79D06A3F386Q39589760-6B5A91BC-1753-4159-B155-E13C663529D9Q39918424-2B1367DE-753F-4669-92B4-F1BB12373BE8Q39965612-7F40EBBD-8CF5-42CD-B90A-838B1E12E51AQ40091988-38F26C3C-F99B-460E-AF80-E5CE1FF19BECQ41769139-63C828D3-EB2E-417D-B159-7BC84B6B3E1DQ42567095-C8673B94-D63A-4A2E-A4B7-F444D1AD59EFQ42933253-1083077C-641D-467E-A77D-97EAE7F484BBQ45884964-53CE9F2E-69A6-4196-99C3-060524FBA701Q47815070-E81E1449-534B-4D35-8574-7AA5E8A49E54Q49211752-FF8AA477-D396-49DF-8F17-C804AD5BC464Q54626084-809E61DE-C9E4-4FD6-A0E8-10DF554BDF79
P2860
Inhibition of experimental corneal neovascularization by using subconjunctival injection of bevacizumab (Avastin).
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Inhibition of experimental cor ...... tion of bevacizumab (Avastin).
@en
Inhibition of experimental cor ...... tival injection of bevacizumab
@nl
type
label
Inhibition of experimental cor ...... tion of bevacizumab (Avastin).
@en
Inhibition of experimental cor ...... tival injection of bevacizumab
@nl
prefLabel
Inhibition of experimental cor ...... tion of bevacizumab (Avastin).
@en
Inhibition of experimental cor ...... tival injection of bevacizumab
@nl
P2093
P1433
P1476
Inhibition of experimental cor ...... tion of bevacizumab (Avastin).
@en
P2093
Eung Kweon Kim
Sang Woo Kim
Sunwoong Kim
Tae-Im Kim
P304
P356
10.1097/ICO.0B013E31815CF67D
P577
2008-04-01T00:00:00Z